Strategic Partnerships Segal Trials recently announced a strategic partnership with Cybin for a multinational pivotal Phase 3 program, signaling openness to collaboration with larger biotech players and offering a potential channel for joint-custody trials, sponsorship opportunities, and expanded research capabilities.

Expansion Potential The company operates seven sites in South Florida with a growing team and a recent site expansion history, indicating capacity to scale clinical operations for sponsors seeking regional access to psychiatry, neurology, addiction, and women’s health trials.

Specialized Expertise Core focus areas include psychiatry, neurology, addiction, insomnia, infectious diseases, vaccines, and women’s health, enabling targeted conversations with sponsors pursuing these therapeutic areas and potential for site-level enrollment acceleration.

Mid-Market Position With estimated revenue in the mid tens of millions and a staff size around 100+, Segal Trials sits between boutique and large CROs, offering a compelling blend of personalized service and scalable capabilities for mid-size Phase I-IV programs.

Local Access Advantage Florida-based network provides proximity benefits for U.S. sponsors seeking efficient patient recruitment, faster site activations, and regulatory familiarity, particularly for trials in psychiatry, neurology, and women’s health that require diverse regional enrollment.